small molecule

QULIPTA

ATOGEPANT

Loss of exclusivityFebruary 2043latest FDA-listed patent expiry

CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand name	QULIPTA
Active ingredient	ATOGEPANT
Strength	10MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	September 2021
Marketing status	RX

Listed patents

Patent	Expires	Type
12350259	February 2043	use U-4234
12622897	September 2042	use U-4536
12465598	September 2042	use U-4355
12090148	July 2041	use U-3534
12383545	June 2039	use U-3534
8754096	September 2035	substance, product
10117836	January 2035	product
9850246	March 2033	substance
9499545	November 2031	substance, product

Regulatory exclusivity

Code	Expires
NCE	September 2026
I-909	April 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from AbbVie Inc.